Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W.

Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20.

2.

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.

von Tresckow J, Cramer P, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Illmer T, Klaproth H, Estenfelder S, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M.

Leukemia. 2019 May;33(5):1161-1172. doi: 10.1038/s41375-018-0313-8. Epub 2018 Dec 19.

PMID:
30568174
3.

Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.

Rinaldetti S, Pfirrmann M, Manz K, Guilhot J, Dietz C, Panagiotidis P, Spiess B, Seifarth W, Fabarius A, Müller M, Pagoni M, Dimou M, Dengler J, Waller CF, Brümmendorf TH, Herbst R, Burchert A, Janβen C, Goebeler ME, Jost PJ, Hanzel S, Schafhausen P, Prange-Krex G, Illmer T, Janzen V, Klausmann M, Eckert R, Büschel G, Kiani A, Hofmann WK, Mahon FX, Saussele S.

Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):266-271. doi: 10.1016/j.clml.2018.02.004. Epub 2018 Feb 8.

4.

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A.

Leukemia. 2018 Apr;32(4):1054. doi: 10.1038/leu.2017.348. Epub 2018 Jan 30.

PMID:
29381150
5.

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Schütz C, Inselmann S, Saussele S, Dietz CT, Mu Ller MC, Eigendorff E, Brendel CA, Metzelder SK, Bru Mmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Xavier Mahon F, Pfirrmann M, Burchert A.

Leukemia. 2017 Apr;31(4):829-836. doi: 10.1038/leu.2017.9. Epub 2017 Jan 11. Erratum in: Leukemia. 2018 Jan 30;:.

PMID:
28074067
6.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.

Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.

PMID:
26549589
7.

NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis.

Kurbacher CM, Fietz T, Diel IJ, Egert M, Hurtz HJ, Lück A, Weide R, Salat C, Wolff T, Zaiss M, Klare P, Losem C, Illmer T, Weißenborn G, Steffens CC, Schulze M, Tesch H, Oskay-Oezcelik G, Teichmann B, Harde J, Scheuerlein RW.

Oncol Res Treat. 2015;38(5):221-9. doi: 10.1159/000381631. Epub 2015 May 4.

8.

Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.

Brendel C, Teichler S, Millahn A, Stiewe T, Krause M, Stabla K, Ross P, Huynh M, Illmer T, Mernberger M, Barckhausen C, Neubauer A.

PLoS One. 2015 Apr 22;10(4):e0123181. doi: 10.1371/journal.pone.0123181. eCollection 2015.

9.

Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.

Lück HJ, Lübbe K, Reinisch M, Maass N, Feisel-Schwickardi G, Tomé O, Janni W, Aydogdu M, Neunhöffer T, Ober A, Aktas B, Park-Simon TW, Schumacher C, Höffkes HG, Illmer T, Wagner H, Mehta K, von Minckwitz G, Nekljudova V, Loibl S.

Breast Cancer Res Treat. 2015 Jan;149(1):141-9. doi: 10.1007/s10549-014-3217-y. Epub 2014 Dec 18.

PMID:
25519041
10.

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Schetelig J, Schaich M, Schäfer-Eckart K, Hänel M, Aulitzky WE, Einsele H, Schmitz N, Rösler W, Stelljes M, Baldus CD, Ho AD, Neubauer A, Serve H, Mayer J, Berdel WE, Mohr B, Oelschlägel U, Parmentier S, Röllig C, Kramer M, Platzbecker U, Illmer T, Thiede C, Bornhäuser M, Ehninger G; Study Alliance Leukemia.

Leukemia. 2015 May;29(5):1060-8. doi: 10.1038/leu.2014.335. Epub 2014 Dec 1.

PMID:
25434303
11.

MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells.

Arabanian LS, Fierro FA, Stölzel F, Heder C, Poitz DM, Strasser RH, Wobus M, Borhäuser M, Ferrer RA, Platzbecker U, Schieker M, Docheva D, Ehninger G, Illmer T.

Haematologica. 2014 Jun;99(6):997-1005. doi: 10.3324/haematol.2013.097675. Epub 2014 Feb 28.

12.

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M.

N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.

13.

MiR-134-mediated β1 integrin expression and function in mesenchymal stem cells.

Poitz DM, Stölzel F, Arabanian L, Friedrichs J, Docheva D, Schieker M, Fierro FA, Platzbecker U, Ordemann R, Werner C, Bornhäuser M, Strasser RH, Ehninger G, Illmer T.

Biochim Biophys Acta. 2013 Dec;1833(12):3396-3404. doi: 10.1016/j.bbamcr.2013.10.003. Epub 2013 Oct 15.

14.

High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.

Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, Einsele H, Ho AD, Serve H, Berdel WE, Mayer J, Schmitz N, Krause SW, Neubauer A, Baldus CD, Schetelig J, Bornhäuser M, Ehninger G.

J Clin Oncol. 2013 Jun 10;31(17):2094-102. doi: 10.1200/JCO.2012.46.4743. Epub 2013 Apr 29.

PMID:
23630210
15.

Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.

Stölzel F, Hackmann K, Kuithan F, Mohr B, Füssel M, Oelschlägel U, Thiede C, Röllig C, Platzbecker U, Schetelig J, Illmer T, Schaich M, Seliger B, Hartmann A, Baretton G, Zietz C, Ehninger G, Schrock E, Bornhäuser M.

Transplantation. 2012 Apr 15;93(7):744-9. doi: 10.1097/TP.0b013e3182481113.

PMID:
22314337
16.

Respiratory failure in patients undergoing allogeneic hematopoietic SCT--a randomized trial on early non-invasive ventilation based on standard care hematology wards.

Wermke M, Schiemanck S, Höffken G, Ehninger G, Bornhäuser M, Illmer T.

Bone Marrow Transplant. 2012 Apr;47(4):574-80. doi: 10.1038/bmt.2011.160. Epub 2011 Sep 19.

PMID:
21927036
17.

miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.

Ovcharenko D, Stölzel F, Poitz D, Fierro F, Schaich M, Neubauer A, Kelnar K, Davison T, Müller-Tidow C, Thiede C, Bornhäuser M, Ehninger G, Brown D, Illmer T.

Exp Hematol. 2011 Oct;39(10):1030-1042.e7. doi: 10.1016/j.exphem.2011.07.008. Epub 2011 Jul 22.

PMID:
21784052
18.

MicroRNA29a regulates the expression of the nuclear oncogene Ski.

Teichler S, Illmer T, Roemhild J, Ovcharenko D, Stiewe T, Neubauer A.

Blood. 2011 Aug 18;118(7):1899-902. doi: 10.1182/blood-2010-09-306258. Epub 2011 Jun 17.

19.

Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia.

Illmer T, Babatz J, Pursche S, Stölzel F, Schuler U, Schaich M, Ehninger G.

Mycoses. 2011 Jul;54(4):e143-7. doi: 10.1111/j.1439-0507.2010.01860.x. Epub 2010 Mar 22.

PMID:
20337942
20.

Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.

Meyer M, Rübsamen D, Slany R, Illmer T, Stabla K, Roth P, Stiewe T, Eilers M, Neubauer A.

PLoS One. 2009 Nov 5;4(11):e7768. doi: 10.1371/journal.pone.0007768.

21.

Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation.

Bornhäuser M, Oelschlaegel U, Platzbecker U, Bug G, Lutterbeck K, Kiehl MG, Schetelig J, Kiani A, Illmer T, Schaich M, Theuser C, Mohr B, Brendel C, Fauser AA, Klein S, Martin H, Ehninger G, Thiede C.

Haematologica. 2009 Nov;94(11):1613-7. doi: 10.3324/haematol.2009.007765.

22.

The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.

Röllig C, Illmer T.

Cancer Treat Rev. 2009 Aug;35(5):425-30. doi: 10.1016/j.ctrv.2009.04.007. Epub 2009 May 22. Review.

PMID:
19464807
23.

Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics.

Strunk CJ, Platzbecker U, Thiede C, Schaich M, Illmer T, Kang Z, Leahy P, Li C, Xie X, Laughlin MJ, Lazarus HM, Gerson SL, Bunting KD, Ehninger G, Tse W.

Am J Hematol. 2009 May;84(5):308-9. doi: 10.1002/ajh.21396.

24.

Rhinocerebral zygomycosis and subsequent treatment decisions in a young patient with AML.

von Bonin M, Hochauf K, Monecke S, Radke J, Thiede C, Bornhäuser M, Platzbecker U, Ehninger G, Illmer T.

Leuk Res. 2009 Jul;33(7):e88-90. doi: 10.1016/j.leukres.2009.01.033. No abstract available.

PMID:
19307017
25.

HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia.

Oelschlaegel U, Mohr B, Schaich M, Schäkel U, Kroschinsky F, Illmer T, Ehninger G, Thiede C.

Cytometry B Clin Cytom. 2009 Sep;76(5):321-7. doi: 10.1002/cyto.b.20475.

26.

Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival.

Guo Y, Köck K, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M.

Clin Cancer Res. 2009 Mar 1;15(5):1762-9. doi: 10.1158/1078-0432.CCR-08-0442. Epub 2009 Feb 24.

27.

The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia.

Seifert H, Mohr B, Thiede C, Oelschlägel U, Schäkel U, Illmer T, Soucek S, Ehninger G, Schaich M; Study Alliance Leukemia (SAL).

Leukemia. 2009 Apr;23(4):656-63. doi: 10.1038/leu.2008.375. Epub 2009 Jan 8.

PMID:
19151774
28.

Detection of herpesvirus and adenovirus co-infections with diagnostic DNA-microarrays.

Müller R, Ditzen A, Hille K, Stichling M, Ehricht R, Illmer T, Ehninger G, Rohayem J.

J Virol Methods. 2009 Feb;155(2):161-6. doi: 10.1016/j.jviromet.2008.10.014. Epub 2008 Dec 2.

PMID:
19022297
29.

AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.

Lindner LH, Ostermann H, Hiddemann W, Kiani A, Würfel M, Illmer T, Karsch C, Platzbecker U, Ehninger G, Schleyer E.

Int J Hematol. 2008 Nov;88(4):381-386. doi: 10.1007/s12185-008-0171-7. Epub 2008 Oct 4.

PMID:
18836794
30.

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium.

von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhäuser M.

Bone Marrow Transplant. 2009 Feb;43(3):245-51. doi: 10.1038/bmt.2008.316. Epub 2008 Sep 29.

PMID:
18820709
31.

Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.

Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R, Illmer T, Wang Y, Hosius C, Nikolova Z, Bornhäuser M, Dresemann G.

Curr Clin Pharmacol. 2008 Sep;3(3):198-203.

32.

Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.

Bornhäuser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hänel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G.

Clin Cancer Res. 2008 Sep 1;14(17):5585-93. doi: 10.1158/1078-0432.CCR-08-0894.

33.

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.

Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D.

Ann Oncol. 2009 Jan;20(1):175-81. doi: 10.1093/annonc/mdn548. Epub 2008 Aug 7.

PMID:
18687982
34.

Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia.

Fierro FA, Brenner S, Oelschlaegel U, Jacobi A, Knoth H, Ehninger G, Illmer T, Bornhäuser M.

Leukemia. 2009 Feb;23(2):393-6. doi: 10.1038/leu.2008.182. Epub 2008 Jul 10. No abstract available.

PMID:
18615106
35.

Cyclic severe elevated procalcitonin serum levels in a patient with post polycythemic myelofibrosis carrying a V617F-JAK2 mutation.

Stölzel F, Babatz J, Thiede C, Siegert G, Illmer T, Ehninger G, Schaich M.

Ann Hematol. 2008 Dec;87(12):1021-2. doi: 10.1007/s00277-008-0517-5. Epub 2008 Jun 12. No abstract available.

PMID:
18548249
36.

Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

Haentzschel I, Freiberg-Richter J, Platzbecker U, Kiani A, Schetelig J, Illmer T, Ehninger G, Schleyer E, Bornhäuser M.

Bone Marrow Transplant. 2008 Jul;42(2):113-20. doi: 10.1038/bmt.2008.85. Epub 2008 Mar 24.

PMID:
18362900
37.

FLT3 kinase inhibitors in the management of acute myeloid leukemia.

Illmer T, Ehninger G.

Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 1:S24-34. Review.

PMID:
18282363
38.

BCR/ABL expression of myeloid progenitors increases beta1-integrin mediated adhesion to stromal cells.

Fierro FA, Taubenberger A, Puech PH, Ehninger G, Bornhauser M, Muller DJ, Illmer T.

J Mol Biol. 2008 Apr 4;377(4):1082-93. doi: 10.1016/j.jmb.2008.01.085. Epub 2008 Feb 5.

PMID:
18313694
39.

Identification of acute myeloid leukaemia associated microRNA expression patterns.

Isken F, Steffen B, Merk S, Dugas M, Markus B, Tidow N, Zühlsdorf M, Illmer T, Thiede C, Berdel WE, Serve H, Müller-Tidow C.

Br J Haematol. 2008 Jan;140(2):153-61. doi: 10.1111/j.1365-2141.2007.06915.x.

PMID:
18173753
40.

Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.

Schaich M, Schlenk RF, Al-Ali HK, Döhner H, Ganser A, Heil G, Illmer T, Krahl R, Krauter J, Sauerland C, Büchner T, Ehninger G.

Haematologica. 2007 Jun;92(6):763-70.

41.

Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro.

Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, Boxberger S, Bornhäuser M.

Cell Prolif. 2007 Jun;40(3):355-66.

PMID:
17531080
42.

Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient.

Pöhlmann C, Schetelig J, Reuner U, Bornhäuser M, Illmer T, Kiani A, Ehninger G, Jacobs E, Rohayem J.

Clin Infect Dis. 2007 Jun 15;44(12):e118-20. Epub 2007 May 2.

PMID:
17516391
43.

Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma.

Oelschlaegel U, Bornhauser M, Boxberger S, Kroschinsky F, Illmer T, Hoelig K, Calandra G, Ehninger G, Platzbecker U.

Ann Hematol. 2007 Aug;86(8):569-73. Epub 2007 Apr 17.

PMID:
17437111
44.

A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography.

Illmer T, Thiede HM, Thiede C, Bornhäuser M, Schaich M, Schleyer E, Ehninger G.

J Pharmacol Toxicol Methods. 2007 Jul-Aug;56(1):23-7. Epub 2007 Feb 23.

PMID:
17395497
45.

Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.

Bornhäuser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C; AML SHG 96 study group.

Blood. 2007 Mar 1;109(5):2264-5; author reply 2265. No abstract available.

46.

Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias.

Illmer T, Schaich M, Ehninger G, Thiede C; DSIL2003 AML study group.

Haematologica. 2007 Jan;92(1):137-8.

47.

F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.

Bonin M, Pursche S, Bergeman T, Leopold T, Illmer T, Ehninger G, Schleyer E, Bornhauser M.

Bone Marrow Transplant. 2007 Feb;39(4):201-6. Epub 2007 Jan 8.

PMID:
17211431
48.

Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping.

Thiede C, Creutzig E, Illmer T, Schaich M, Heise V, Ehninger G, Landt O.

Leukemia. 2006 Oct;20(10):1897-9. Epub 2006 Sep 7. No abstract available.

PMID:
17041639
49.

Association with the single-nucleotide polymorphism (Glu785Lys) of the granulocyte colony-stimulating factor receptor with myelodysplastic syndromes and acute myeloid leukemia with multlineage dysplasia.

Platzbecker U, Germing U, Schäkel U, Illmer T, Soucek S, Schaich M, Ehninger G, Thiede C.

Leukemia. 2006 Dec;20(12):2188-9. Epub 2006 Oct 5. No abstract available.

PMID:
17024119
50.

Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation.

Bornhauser M, Thiede C, Babatz J, Schetelig J, Illmer T, Kiani A, Platzbecker U, Herr W, Rieber EP, Ehninger G, Schmitz M.

Leukemia. 2006 Nov;20(11):2055-7. Epub 2006 Aug 31. No abstract available.

PMID:
16990776

Supplemental Content

Loading ...
Support Center